Nature Reviews Gastroenterology & Hepatology

Article	Citations
Regulating protease homeostasis in irritable bowel syndrome	730
Hybrid EASL Congress 2023	528
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity	497
Zolbetuximab treatment in metastatic gastric cancer	495
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	484
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	425
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	412
Digestive Disease Week 2022	374
Mapping neuroimmune interactions in the gut	362
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	332
2023 FDA approvals in gastroenterology and hepatology	326
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	323
Western lifestyle, metaflammation and the cell of origin of colon cancer	319
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	311
Large language models for clinical decision support in gastroenterology and hepatology	299
Black–White disparities across the colorectal cancer care continuum in the USA	280
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	245
Leveraging diet to engineer the gut microbiome	226
Nomenclature of HBV core protein-targeting antivirals	224
Artificial intelligence and automation in endoscopy and surgery	215
Hepatic IRF3 in glucose intolerance	209
Oral microbiome therapy efficacious for recurrent C. difficile infection	195
Wound healing in the colon	190
GWAS reveals variants for alcohol-related hepatocellular carcinoma	187
A crucial Fusobacterium nucleatum clade in colorectal cancer	185

The global burden of coeliac disease: opportunities and challenges	183
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	180
Inflammatory bowel disease in pregnancy and breastfeeding	175
Decoding therapy resistance in liver tumours: a giant leap	171
New understanding of hepatobiliary MRI	169
Lessons from incretin-based therapy in MASH and obesity	165
Metastatic pancreatic cancer and the liver	162
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	160
Bacteriophages and their potential for treatment of gastrointestinal diseases	159
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	154
Integrated systems approach to identify environmental factors in intestinal inflammation	149
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	143
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	132
Metabolic diseases in the East Asian populations	131
Lanifibranor and NASH resolution	130
Implications of the evolving knowledge of the genetic architecture of MASLD	128
Estimating dietary intake from human stool DNA	123
Characterizing the genomic landscape of colorectal cancer	118
HDCA ameliorates NAFLD in mice	116
Probiotics for preterms: sharing complex decision-making	115
The path to successful hepatitis C elimination in Spain	113
Liver, ageing and disease	113
SSRIs and depression: role of gut–brain communication	112
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	110
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	109
Medical therapy of paediatric inflammatory bowel disease	106
Human intestinal B cells in inflammatory diseases	106
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment	102
Current and future colorectal cancer screening strategies	101
Preventing the progression of cirrhosis to decompensation and death	100
ECCO’24	99
Author Correction: Hepatic immune regulation and sex disparities	99
NAFLD prevalence in older patients with T2DM	96
Phase III results for first-line treatment for metastatic colorectal cancer	95
Microbiota and colorectal cancer — controlling for confounders challenges associations	94
Gut microbiome and autism spectrum disorder	93
Enteric nervous system transfers stress to the gut	91
GLP1R agonists in NAFLD: a promising therapy on the horizon	88
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	87
Transforming the landscape of liver cancer detection and care	86
Artificial intelligence in liver cancer — new tools for research and patient management	85
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	85
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	81
The future of pathology in gastroenterology and hepatology	80
Foundations of gastrointestinal-based drug delivery and future developments	79
Hepatic glucose metabolism in the steatotic liver	77
Hepatic inflammatory responses in liver fibrosis	76
SMART cancer risk prediction	74
Immunoregulatory role of enteric glia	74
Liver dialysis in ACLF	74

AI predicts pancreatic cancer risk	71
Elucidating the transmission landscape of the human microbiome	69
Gut bacteria go on record	65
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel	64
Postbiotics — when simplification fails to clarify	60
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	59
International collaborative research to improve gallbladder cancer prevention	59
MASLD as a non-communicable disease	56
Nifty new tools for microbiome treatment design	56
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	54
Hepatitis E virus: from innate sensing to adaptive immune responses	54
A new era in obesity management	52
Nutrient sensing and small intestinal enteric neurons	51
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests	50
Revisiting fibrosis in inflammatory bowel disease: the gut thickens	50
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	49
Danger! P2Y14 receptor links cell death to liver fibrosis	48
Cathepsin S in liver fibrogenesis	47
Tirzepatide to treat obesity: phase III results	47
A novel pathomics signature for gastric cancer	47
Natural history of NAFLD: knowns and unknowns	42
Bridging the gap: increasing MENA representation in MASLD clinical trials	42
Antibiotic-perturbed microbiota and the role of probiotics	40
The steatotic liver disease burden paradox: unravelling the key role of alcohol	38
Therapeutic landscape and future direction of metastatic colorectal cancer	38
Origin of CAFs in colorectal cancer	37
Classifying compounds as prebiotics — scientific perspectives and recommendations	36
Cellular and molecular basis of proximal small intestine disorders	35
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	34
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	34
Commensal fungi in intestinal health and disease	31
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	31
Author Correction: Improving IBD outcomes in the era of many treatment options	30
Long-term normothermic liver perfusion	30
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	30
Public health policies to prevent alcohol-related liver disease	29
Alcohol-free and low-strength drinks: friend or foe?	29
Justice, equity, diversity and inclusion in gastroenterology and hepatology	29
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	28
Author Correction: Current and future colorectal cancer screening strategies	28
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	27
Diet-driven microbiome restoration associated with cardiometabolic benefits	27
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	26
A Roadmap for the Human Gut Cell Atlas	26
Global epidemiology of cirrhosis — aetiology, trends and predictions	25
Resmetirom safe for nonalcoholic fatty liver disease	25
Hippo signalling in the liver: role in development, regeneration and disease	25
New target and timing in PDAC immunotherapy?	25
Digestive Disease Week 2023	24
Elafibranor in primary biliary cholangitis	23
A resource for the food microbiome and its links with the human microbiome	23
ECCO’25	23
Envisioning how to advance the MASH field	22
Food inequity and insecurity and MASLD: burden, challenges, and interventions	22
Digestive Disease Week 2025	21
Intermittent fasting for NASH and HCC in mice	21
Location, location, location — spatial insight into hepatic macrophage populations	21
Deciphering potential implications of dietary microplastics for human health	21
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	20
Human liver tissue in a mouse host	20
Nanoparticles in NAFLD therapeutics	20
Gastrointestinal health and the environment: a bidirectional relationship	20
Follow-up of SER-109 for recurrent C. difficile	20
Amitriptyline as second-line treatment for IBS in primary care settings	19
HCV direct-acting antiviral therapy adherence in people who inject drugs	19
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	19
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	19
COVID-19 and liver disease: where are we now?	18
Lactylation and HCC progression	18
IL-17A-producing CD8+ T cells in pancreatic cancer	18
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	17
Gastrointestinal post-acute COVID-19 syndrome	17
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	16
Paving the way: the road to be taken for proper NAFLD health care	16
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	16
Biologic agents for IBD come of age as host–microbe interactions emerge	16
Liver steatosis and fibrosis in China	14
Elucidating the nutrient preferences of mouse gut bacteria	14
Mucus secretion from colonic goblet cells is regulated by autophagy and ER stress	14
Mapping the malignant transformation from polyps to CRC	14

Elucidating the link between clonal haematopoiesis and chronic liver disease	14
Neoadjuvant chemotherapy for operable colon cancer	13
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards	13
Maintaining remission in ulcerative colitis	13
Combination treatment further extends survival	13
AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD	13
Host–pathobiont interactions in Crohn’s disease	13
Secretory IgA: controlling the gut microbiota	12
Author Correction: Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	12
‘Dark matter’ beyond the bacteria in faecal microbiota transplantation	12
Positioning therapies for the management of inflammatory bowel disease	12
Paracellular permeability and tight junction regulation in gut health and disease	11
Actions of thyroid hormones and thyromimetics on the liver	11
Fermented foods and gastrointestinal health: underlying mechanisms	11
Cellular triads in T cell liver tumours	11
Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions	11
Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy	10
Liquid biopsy guides anti-EGFR rechallenge in metastatic CRC	10
A bloody disgrace — time to change patient safety culture	10
Liver transplantation plus chemotherapy improved survival in patients with colorectal liver metastasis	10
Redefining cancer care: the case for an onco-gastroenterology subspecialty	9
Rethinking gastric cancer prevention through an immigrant health lens	9
The war on pancreatic cancer: progress and promise	9
IgG4-related diseases of the digestive tract	9
Next-generation enteric neuroscience — fostering the future of the field	9
Sex bias in clinical trials in gastroenterology and hepatology	9
Diversity, development and immunoregulation of enteric neurons	9
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation	8
Mechanisms of metastatic colorectal cancer	8
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity	8
Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease	8
Anatomy-preserving adjustable intragastric balloon is safe and promotes durable weight loss	8
Precision models in hepatocellular carcinoma	8
CXCR2 inhibition in NASH-HCC	8
An expert panel Consensus Statement on ALD without experts by experience	7
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders	7
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?	7
Liraglutide treatment in children with obesity	7
Rome Foundation Working Team Report on overlap in disorders of gut–brain interaction	7
The appendix and ulcerative colitis — an unsolved connection	7
Understanding the therapeutic toolkit for inflammatory bowel disease	7
Connecting with the community	7
NAFLD, MAFLD and obesity: brothers in arms?	7
Stigma: a major barrier to hepatitis B elimination	7
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications	7
Effect of bariatric surgery on risk of oesophagogastric cancer	6
Machine perfusion of the liver: applications in transplantation and beyond	6
Author Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	6
Contrasting aspects of human excreta	6
Metabolic health across the ages: how microbiota members support our well-being	6
Pouchitis: pathophysiology and management	6
Human hepatocyte organoids model early NAFLD	6
Crosstalk between enteric neurons and colorectal cancer stem cells influences self-renewal	6
Fetal liver development and implications for liver disease pathogenesis	6
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	6
Rhythmicity of infant microbiota and dietary effects	6
Colonoscopy screening and risk of CRC	5
Safety of in utero exposure to maternal IBD pharmacotherapies	5
Liver fibrosis with methotrexate — an overestimated risk?	5
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	5
Gut feelings: mechanosensing in the gastrointestinal tract	5
The immune microenvironment in gastric adenocarcinoma	5
Combination therapy with methotrexate in paediatric Crohn’s disease	5
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape	5
Mechanisms and pathophysiology of Barrett oesophagus	5
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	5
CIDEB variants protect against liver disease	5
Hepatitis C testing, treatment and prevention in low- and middle-income country prisons	5
Benign liver tumours: understanding molecular physiology to adapt clinical management	5
Novel interventions against alcohol-related liver disease	5
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	5
Women in endoscopy: leading the way	5
Ultra-processed diet increases CRC risk	4
Investigating two versus three doses of mRNA vaccine in patients with cirrhosis	4
A prime role for PIEZO2 in DRG neurons in mechanosensation in the gut	4
A link to the past	4
Embracing many rainbows: the realities of being a gay physician, mother and patient	4
Development of MKK4 inhibitors for liver regeneration	4
Break the taboo with poo	4
Role of intestinal B cells in NASH and liver fibrosis	4
Upadacitinib therapy for Crohn’s disease	4
The global burden of inflammatory bowel disease: from 2025 to 2045	4
Fazirsiran shows promise for liver disease in AAT	4
Multi-omic links between gut microbiome and cardiovascular disease	3
Therapeutic developments in pancreatic cancer	3
Hepatic vagus nerve relays signals to the brain that can alter food intake	3
DNA methylation biomarker in Crohn’s disease	3
Mycobiota–host immune interactions in IBD: coming out of the shadows	3
Rifaximin-α for ALD: phase II results	3
Challenges in gastrointestinal research in Latin America	3
Dietary management of adults with IBD — the emerging role of dietary therapy	3
Perianal fistula surgical closure in Crohn’s disease	3
Air pollution and oesophageal cancer risk	3
Next generation of gastrointestinal electrophysiology devices	3
Mutations linked to chemotherapy resistance in colorectal cancer	3